대장암 치료제 시장 : 치료 유형별, 유통채널별, 암 유형별, 지역별 규모, 점유율 및 성장 분석과 산업 예측(2026-2033년)

Colorectal Cancer Therapeutics Market size was valued at USD 12.77 Billion in 2024 and is poised to grow from USD 13.4 Billion in 2025 to USD 19.64 Billion by 2033, growing at a CAGR of 4.9% during the forecast period (2026-2033).

The colorectal cancer therapeutics market is characterized by a diverse array of treatments aimed at inhibiting the growth, spread, and recurrence of colorectal cancer cells, often administered in combination to enhance efficacy. Ongoing research and clinical trials focus on discovering innovative therapeutic options tailored for colorectal cancer patients. This extensive market encompasses chemotherapy, targeted therapies, and immunotherapies designed to reduce cancer cell proliferation, induce apoptosis, and disrupt key pathways associated with disease progression. The rising incidence of colorectal cancer worldwide serves as a significant driver for market expansion, underscoring the need for effective treatment solutions. Additionally, the rise of biosimilars for biologic drugs enhances competition and may lower treatment costs, offering patients more affordable therapeutic alternatives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Colorectal Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Colorectal Cancer Therapeutics Market Segments Analysis

Global Colorectal Cancer Therapeutics Market is segmented by Drug Class, Cancer Type, Distribution Channel, and region. Based on Drug Class, the market is segmented into Chemotherapy, Immunotherapy, and Others. Based on Cancer Type, the market is segmented into Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Colorectal Cancer Therapeutics Market

One of the key market drivers for the global colorectal cancer therapeutics market is the increasing prevalence of colorectal cancer worldwide. Factors such as aging populations, lifestyle changes, and dietary habits contribute to higher incidence rates, prompting a growing demand for innovative treatment options. Additionally, advancements in personalized medicine and targeted therapies are enhancing treatment efficacy, thus attracting investments and driving research and development in this sector. Increased awareness about early detection and preventive measures, along with more comprehensive screening programs, are further amplifying the need for effective therapeutics, creating a robust growth environment for the market.

Restraints in the Colorectal Cancer Therapeutics Market

One significant market restraint for the global colorectal cancer therapeutics market is the high cost of treatment and associated healthcare expenses. Many advanced therapies, including biologics and targeted treatments, come with substantial price tags that can limit patient access and adherence to prescribed regimens. This financial burden not only affects individual patients but also puts pressure on healthcare systems and insurers, potentially leading to increased out-of-pocket costs. Additionally, the variability in reimbursement policies across regions can create disparities in treatment availability, hindering market growth and limiting the reach of innovative therapies.

Market Trends of the Colorectal Cancer Therapeutics Market

The Colorectal Cancer Therapeutics market is witnessing a significant shift towards the increasing adoption of immunotherapy, marking a transformative phase in treatment options. Immune checkpoint inhibitors and cancer vaccines are being increasingly recognized for their efficacy, particularly in patients with high microsatellite instability (MSI-H) tumors, thereby expanding the treatment landscape. The continued emergence of new immunotherapy agents, coupled with innovative combinations alongside conventional chemotherapy, is enhancing patient outcomes by prolonging survival and improving overall quality of life. As awareness and application of these therapies grow, they are expected to redefine standard care practices in colorectal cancer management.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Colorectal Cancer Therapeutics Market by Drug Class

• Market Overview
• Chemotherapy
• Immunotherapy
• Others

Colorectal Cancer Therapeutics Market by Cancer Type

• Market Overview
• Colorectal Adenocarcinoma
• Gastrointestinal Carcinoid Tumors
• Others

Colorectal Cancer Therapeutics Market byDistribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Colorectal Cancer Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• Amgen, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lilly (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncolytics Biotech Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantKwest, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Halozyme Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments